An Assessment of the Increase in Fetal Hemoglobin Gene Expression in the K562 Cell Line Treated by Dendrosomal Nano-curcumin

Authors
H. Shirzad 1
H. Shirzad 1
M. Poursangi 2
H. Maghsoudi 2
S. Jalili 1
1 Research Institute of Police Science and Social Studies, Tehran, Iran
2 Department of Biology, Faculty of Basic Sciences, Payame Noor University, PNU Ray, Tehran, Iran
Abstract
Objective: Fetal hemoglobin is the predominant hemoglobin expressed by gamma globin. However, in adults, fetal hemoglobin normally reduces to very low levels of the total hemoglobin. The increase in levels of fetal hemoglobin can ameliorate the severity of β-hemoglobin disorders such as sickle cell disease and beta-thalassemia. Currently, drugs that have been used for induction of Fetal hemoglobin (HbF) have short-term effects. Dendrosomal nano-curcumin (DNC), which has high solubility and absorption, is able to detect different targets in the cell and affect gene expression. LSD1 is one of the most important gamma globin inhibitors. In this study, we examine the capability of DNC to inhibit the expression of LSD1, GATA1, and FOG1 as well as the increase in gamma globin expression.
Methods: We used the K562 cell line for the MTT assay and treatment by DNC. Then the effect of DNC on the increase in expression level of γ-globin, decrease expression level of LSD1 and transcription factors, GATA1 and FOG1was investigated by Real time PCR.
Results: Data acquired from gene expression assays indicated that DNC induced gamma globin expression and decreased expressions of LSD1, GATA1, and FOG1 in a time and dose-dependent manner.
Conclusion: Inhibition of LSD1, GATA1, and FOG1 expressions via DNC led to increased gamma globin expression. These results showed that DNC could be a promising treatment for beta-thalassemia and sickle cell disorders, and possibly reduce the severity of symptoms of these patients through the induction of fetal hemoglobin.

Keywords

[1]  Asgharian AM, Banan M, Najmabadi H. Evaluation of knocking down of the RNAi mediated gamma globin repressor into K562 cells, for gene therapy of beta-thalassemia. Pejouhandeh 2011; 16(5): 234-40.
[2]  Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Blood 2012; 120(15): 2945-53.
[3]  Bauer DE, Orkin SH. Update on fetal hemoglobin gene regulation in hemoglobinopathies. Curr Opin Pediatr 2011; 23(1): 1-8.
[4]  Dehghanifard A, Kaviani S, Noruzinia M, Soleimani M, Abroun S, Hajifathali A, Pourfathollah A, Mortazavi Y, Ahmadvand M, Mahmoodinia-Meymand M, Kaviani Z, Farshdousti-Hagh M, Saki N. Synergistic effect of sodium butyrate and thalidomide in the induction of fetal hemoglobin expression in erythroid progenitors derived from cord blood CD133 + cells. Zahedan J Res Med Sci (ZJRMS) 2012; 14(7): 29-33.
[5]  Kumarasinghe IR, Woster PM. Synthesis and evaluation of novel cyclic peptide inhibitors of Lysine Specific Demethylase 1. ACS Med Chem Lett 2014; 5: 29-33.
[6]  Ginder GD. Epigenetic regulation of fetal globin gene expression in adult erythroid cells. Transl Res 2015; 165(1): 115-25.
[7]  Amigo JD, Ackermann GE, Cope JJ, Yu M, Cooney JD, Ma D, Langer NB, Shafizadeh E, Shaw GC, Horsely W, Trede NS, Davidson AJ, Barut BA, Zhou Y, Wojiski SA, Traver D, Moran TB, Kourkoulis G, Hsu K, Kanki JP, Shah DI, Lin HF, Handin RI, Cantor AB, Paw BH. The role and regulation of friend of GATA-1 (FOG-1) during blood development in the zebrafish. Blood 2009; 114(21): 4654-63.
[8]  Finotti A, Gasparello J, Breveglieri G, Cosenza LC, Montagner G, Bresciani A, Altamura S, Bianchi N, Martini E, Gallerani E, Borgatti M, Gambari R. Development and characterization of K562 cell clones expressing BCL11A-XL: Decreased hemoglobin production with fetal hemoglobin inducers and its rescue with mithramycin. Exp Hematol 2015; 43(12): 1062-71.
[9]  Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, Aggarwal BB. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008; 76(11): 1590-611.
[10]             Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 2011; 10: 12.
[11]             Shishodia S, Chaturvedi MM, Aggarwal BB. Role of curcumin in cancer therapy. Curr Probl Cancer 2007; 31(4): 243-305.
[12]             Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991; 57(1): 1-7.
[13]             Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269(2): 199-225.
[14]        Fu S, Kurzrock R. Development of curcumin as an epigenetic agent. Cancer 2010; 116(20): 4670-6.
[15]             Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, Maitra A. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 2007; 5: 3.
[16]             Sarbolouki MN, Parsaee S, Kosary P. Mixed micelle proliposomes for preparation of liposomes containing amphotericin B, in-vitro and ex-vivo studies. PDA J Pharm Sci Technol 2000; 54(3): 240-6.
[17]             Babaei E, Sadeghizadeh M, Hassan ZM, Feizi MA, Najafi F, Hashemi SM. Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo. Int Immunopharmacol 2012; 12(1): 226-34.
[18]             Tahmasebi Mirgani M, Isacchi B, Sadeghizadeh M, Marra F, Bilia AR, Mowla SJ, Najafi F, Babaei E. Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells. Int J Nanomedicine 2014; 9: 403-17.
[19]             Abdulla A, Zhao X, Yang F. Natural Polyphenols Inhibit Lysine-Specific Demethylase-1 in vitro. J Biochem Pharmacol Res 2013; 1(1): 56-63.
[20]             Deilami Khiabani Z, Banan M, Asgharian AM, Gharesouran J, Javadi G, Kahrizi K, Najmabadi H. Determination of γ-globin induction levels by different concentrations of hydroxyurea in K562 cell lines for β thalassemia treatment. Medical Sciences 2009; 19(3) :147-53.
[21]             Tahmasebi Mirgani M, Sadeghizadeh M, Najafi F, Mowla SJ. Dendrosomal curcumin induced apoptosis by suppression of pluripotency genes in 5637 bladder cancer cells. Modares Journal of Medical Sciences (Pathobiology) 2013; 16(1): 23-39.
[22]             Finotti A, Bianchi N, Fabbri E, Borgatti M, Breveglieri G, Gasparello J, Gambari R. Erythroid induction of K562 cells treated with mithramycin is associated with inhibition of raptor gene transcription and mammalian target of rapamycin complex 1 (mTORC1) functions. Pharmacol Res 2015; 91: 57-68.
[23]             Alizadeh SH, Kaviani S, Soleimani M, Pourfathollah AA, Amirizadeh N, Kouhkan F, Abroun S, Noruzinia M. Effect On alpha hemoglobin chain expression in K562 cell line. Payavard 2011; 4(3 & 4): 9-17.
[24]             Cao A, Moi P, Galanello R. Recent advances in β-thalassemias. Pediatr Rep 2011; 3(2): e17.
[25]             Langdon SD, Kaufman RE. Gamma-globin gene promoter elements required for interaction with globin enhancers. Blood 1998; 91(1): 309-18.
[26]             Shi L, Cui S, Engel JD, Tanabe O. Lysine-specific demethylase 1 is a therapeutic target for 
fetal hemoglobin induction. Nat Med 2013; 19(3): 291-4.
[27]             Zheng R, Blobel GA. GATA Transcription Factors and Cancer. Genes Cancer 2010; 1(12): 1178-88.
[28]             Shimizu R, Engel JD, Yamamoto M. GATA1-related leukaemias. Nat Rev Cancer 2008; 8(4): 279-87.
Pathobiology Reserach
Volume 19, Issue 4
September 2017
Pages 55-69